Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of hyaluronic acid (HA), a naturally occurring glycosaminoglycan with viscoelastic and anti-inflammatory properties, and serratiopeptidase (SRP), a proteolytic enzyme known for its anti-inflammatory and anti-biofilm effects. The combination is typically formulated as nanogels or gels for local delivery to enhance the control of bacterial biofilms and inflammation. Hyaluronic acid serves as a biocompatible carrier that can encapsulate SRP, providing sustained release and improved stability of the enzyme. This formulation has demonstrated enhanced antimicrobial activity against biofilm-forming bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus compared to free SRP alone. The primary indications are in dental/periodontal therapy (as an adjunct to scaling and root planing) or wound care where both reduction in inflammation and disruption of biofilms are desired[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + serratiopeptidase.